CV Sciences Q4 sales fall

CV Sciences

26/03/2026 20:10

Overview

U.S. hemp extracts seller's Q4 sales declined yr/yr due to lower volumes and regulatory challenges

Company posted positive adjusted EBITDA in Q4, driven by reduced operating expenses and higher margins

CV Sciences completed debt restructuring in Q1 2026 to strengthen financial position

Outlook

Company aims to enhance operating efficiency and drive consistent positive cash flow in 2026

CV Sciences sees opportunity to accelerate growth through strategic acquisitions

Company plans to balance near-term profitability with targeted M&A for improved performance

Result Drivers

LOWER SALES VOLUME - Co said Q4 and FY sales decline was driven by temporary out-of-stock issues for key products and restrictive regulations

OPERATING EXPENSES REDUCED - Co attributed improved adjusted EBITDA and reduced operating loss to lower operating expenses

B2B REVENUE - Sequential Q4 sales increase was mostly due to additional B2B revenue

Company press release: ID:nACSrjP8Qa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
$3.31 mln
Q4 Net Income
-$206,000
Q4 Gross Profit
$1.67 mln
Q4 Operating Expenses
$1.75 mln
Q4 Operating Income
-$75,000
Q4 Pretax Profit
-$204,000


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)